written on 28.03.2014

FDA CRDAC: Novartis' serelaxin not ready for prime time


The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 11-0 in recommending against approval of serelaxin – putting much of the blame for serelaxin’s troubles on the confusing design of the single trial Novartis used to…

Latest Reports